Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report
Open Access
- 24 October 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (1), 96-99
- https://doi.org/10.1016/j.clcc.2020.10.003
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialNature Medicine, 2019
- Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and statusWorld Journal of Clinical Cases, 2018
- Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal CancerJournal of the National Comprehensive Cancer Network, 2016
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2016
- Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerBritish Journal of Cancer, 2015
- Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cellsCell Cycle, 2015
- Significance of human epidermal growth factor receptor 2 expression in colorectal cancerExperimental and Therapeutic Medicine, 2014
- Mir-34: A New Weapon Against Cancer?Molecular Therapy Nucleic Acids, 2014
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trialEuropean Journal of Cancer, 2013
- Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIRPLOS ONE, 2013